In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Adopting a Strategy to Identify Highest Commercial Value Products
A thought leadership article written by Vicki Anastasi, published by the Journal of Medical Device Regulation (JMDR), exploring the challenges of transitioning to the new EU Medical Devices Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) and advising manufactures on how to prioritise their product portfolio to ensure a smooth transition.
-
A Primer for Manufacturers Adjusting to Value-Based Healthcare
A thought leadership article published by MPO Magazine, written by ICON expert Vicki Anastasi, on the challenges of a value-based healthcare market and the importance of demonstrating clinical efficacy and cost impact of new devices. The piece discusses how partnering with an experienced CRO with a track record in clinical evidence generation, economic modelling, and commercialisation can help devices to achieve strong market impact.
-
ICON Rolls Out Digital Platform Developed with Dimension Data
An article published by Fierce Biotech on ICON’s new digital platform developed with Dimension Data. The innovative platform supports digital trials and patient interaction by reducing complexity and cost to ultimately enhance the efficiency and productivity of client pipelines.
-
Improving Pharma R&D Efficiency
With development cycles becoming too long, trial complexity increasing, and greater scrutiny of the economic value of new treatments, pharma R&D business models are under significant pressures to improve R&D efficiency. In an ICON industry survey of pharmaceutical executives and professionals on Pharma R&D Efficiency, the challenges most frequently cited are explored. Learn more in this Applied Clinical Trials Industry Trends 2019 article.
-
Parkinson’s Disease Clinical Trials
An Outsourcing-Pharma (OSP) article exploring Parkinson’s disease clinical trials, featuring commentary from ICON Central Nervous System (CNS) experts Dr Peter Schueler (Sr VP, Drug Development Services) and Haichen Yang (VP, Global Therapeutic Lead). For neurological research areas, digital endpoints may soon be used as primary endpoints, allowing for in-home trials to be conducted over longer periods of time.
-
ICON Issues Financial Guidance for Full Year 2019
ICON announced its financial guidance for the year ended December 31, 2019, featuring commentary from Steve Cutler
-
Centre of the pharmaverse
Patients’ role in their own health has evolved more in the past decade than in the previous six combined. Consequently, an all-encompassing digital era has opened unique opportunities for industry to engage with patients meaningfully, while also creating a modernised healthcare landscape which yields trust and cooperation. Read more in PharmaTimes' January 2019 article, Centre of the pharmaverse, featuring insights from ICON experts Kelly Franchetti and Caroline Forkin.
-
How Value-Based Healthcare Affects Medical Device Development
Read this MPO Magazine article written by ICON expert Vicki Anastasi on how value-based healthcare (VBHC) models are expected to transform the health sector, impacting every aspect from patient care to drug pricing, and how partnering with a CRO can help manufacturers to demonstrate clinical efficacy and cost impact of new devices.
-
Pharma R&D Business Models Under Pressure To Improve Efficiency
Read this World Pharmaceuticals article featuring ICON insights to explore the drug development cost pressures driving the search for savings, and discover why many pharma organisations that institute large-scale operational efficiencies need to integrate efforts if they are to be effective.
-
Ten Developments to Watch Out For in Life Sciences
Read The Irish Times’ article featuring commentary from ICON’s Tom O’Leary on the top digital and technological developments in the life science industry, including mHealth, AI, robotic process automation, blockchain and virtual technologies.
